Abstract: The invention relates to a method for preparing lead (212) for medical use. This method comprises the production of lead (212) by the decay of radium (224) in a generator comprising a solid medium to which the radium (224) is bound, followed by the extraction of the lead (212) from the generator in the form of an aqueous solution A1, characterised in that the lead (212) contained in the aqueous solution A1 is purified from the radiological and chemical impurities, also contained in said aqueous solution, by a liquid chromatography on a column. The invention also relates to an apparatus specially designed for automated implementation in a closed system of said method. It further relates to lead (212) produced by means of this method and this apparatus. Applications: manufacture of radiopharmaceuticals based on lead (212), useful in nuclear medicine for the treatment of cancers, particularly by a-radioimmunotherapy, or for medical imaging, in both humans and animals.

Abstract: An apparatus is for the automated production of a daughter radionuclide from a parent radionuclide using a generator comprising a solid medium onto which the parent nuclide is fixed and whereby the daughter nuclide is formed by radioactive decay of the parent nuclide. The apparatus includes a fluid circuit including a chromatography column having a head port and a tail port, at least one connection port for connecting the generator to the fluid circuit, at least one inlet port for connecting fluid sources to the fluid circuit and at least one valve controlled by an electronic control unit for selectively connecting the chromatography column, the connection port and the at least one inlet port in various configurations.

Abstract: A process for producing a daughter radionuclide from a parent radionuclide includes a) loading the parent radionuclide on a first solid medium contained in a generator and onto which the parent radionuclide is retained and whereby the daughter radionuclide is formed by radioactive decay of the parent radionuclide; b) eluting this medium with a A0 solution so as to recover a A1 solution comprising the daughter radionuclide; c) optionally adjusting the pH of the A1 solution so as to obtain a A1? solution, d) loading this A1 or A1? solution onto the head of a second solid medium contained in a chromatography column; e) first washing said second solid medium with a A2 solution; f) second washing said second solid medium with a A2? solution; g) eluting the daughter radionuclide with a A3 solution. The first washing step is conducted from head to tail of the column and the second washing step and the second eluting step are conducted from tail to head of the column.

Abstract: The present invention concerns a process for producing a daughter radionuclide from a parent radionuclide comprising the purification of the daughter radionuclide on a chromatography column, as well as the apparatus for carrying out such process.

Abstract: The invention relates to a method for preparing lead (212) for medical use. This method comprises the production of lead (212) by the decay of radium (224) in a generator comprising a solid medium to which the radium (224) is bound, followed by the extraction of the lead (212) from the generator in the form of an aqueous solution A1, characterised in that the lead (212) contained in the aqueous solution A1 is purified from the radiological and chemical impurities, also contained in said aqueous solution, by a liquid chromatography on a column. The invention also relates to an apparatus specially designed for automated implementation in a closed system of said method. It further relates to lead (212) produced by means of this method and this apparatus. Applications: manufacture of radiopharmaceuticals based on lead (212), useful in nuclear medicine for the treatment of cancers, particularly by a-radioimmunotherapy, or for medical imaging, in both humans and animals.

Abstract: The invention relates to a method for preparing lead (212) for medical use. This method comprises the production of lead (212) by the decay of radium (224) in a generator comprising a solid medium to which the radium (224) is bound, followed by the extraction of the lead (212) from the generator in the form of an aqueous solution A1, characterized in that the lead (212) contained in the aqueous solution A1 is purified from the radiological and chemical impurities, also contained in said aqueous solution, by a liquid chromatography on a column. The invention also relates to an apparatus specially designed for automated implementation in a closed system of said method. It further relates to lead (212) produced by means of this method and this apparatus. Applications: manufacture of radiopharmaceuticals based on lead (212), useful in nuclear medicine for the treatment of cancers, particularly by a-radioimmunotherapy, or for medical imaging, in both humans and animals.

Abstract: The invention relates to a method for preparing lead (212) for medical use. This method comprises the production of lead (212) by the decay of radium (224) in a generator comprising a solid medium to which the radium (224) is bound, followed by the extraction of the lead (212) from the generator in the form of an aqueous solution A1, characterised in that the lead (212) contained in the aqueous solution A1 is purified from the radiological and chemical impurities, also contained in said aqueous solution, by a liquid chromatography on a column. The invention also relates to an apparatus specially designed for automated implementation in a closed system of said method. It further relates to lead (212) produced by means of this method and this apparatus. Applications: manufacture of radiopharmaceuticals based on lead (212), useful in nuclear medicine for the treatment of cancers, particularly by a-radioimmunotherapy, or for medical imaging, in both humans and animals.

Abstract: The invention relates to a process for producing 228Th from a natural thorium salt, which comprises in succession: a) the separation of the radium from the other radioelements present in this salt, by at least one coprecipitation of the radium by barium sulphate, this coprecipitation comprising: i) the addition of sulphuric acid and a barium salt to an aqueous solution of said natural thorium salt in order to form a barium-radium sulphate coprecipitate and ii) the separation of the coprecipitate from the medium in which it has formed; b) the extraction of the thorium 228 coming from the decay of radium 228 from the coprecipitate thus separated; and, optionally c) the purification and concentration of the 228Th thus extracted. Applications: manufacture of radiopharmaceutical products useful in nuclear medicine, in particular in radioimmunotherapy for the treatment of cancers and AIDS.

Abstract: A chemical element to be very efficiently separated from uranium starting from an acid aqueous phase, in an extraction cycle for the uranium, when this chemical element is present in said phase at a concentration less than that of the uranium, or even as a trace element, and when it is moreover less extractable by the extractant used in this extraction cycle than is the uranium. The chemical element can notably be neptunium(IV) or thorium 228.

Abstract: The invention relates to a process for producing 228Th from a natural thorium salt, which comprises in succession: a) the separation of the radium from the other radioelements present in this salt, by at least one coprecipitation of the radium by barium sulphate, this coprecipitation comprising: i) the addition of sulphuric acid and a barium salt to an aqueous solution of said natural thorium salt in order to form a barium-radium sulphate coprecipitate and ii) the separation of the coprecipitate from the medium in which it has formed; b) the extraction of the thorium 228 coming from the decay of radium 228 from the coprecipitate thus separated; and, optionally c) the purification and concentration of the 228Th thus extracted. Applications: manufacture of radiopharmaceutical products useful in nuclear medicine, in particular in radioimmunotherapy for the treatment of cancers and AIDS.

Abstract: A chemical element to be very efficiently separated from uranium starting from an acid aqueous phase, in an extraction cycle for the uranium, when this chemical element is present in said phase at a concentration less than that of the uranium, or even as a trace element, and when it is moreover less extractable by the extractant used in this extraction cycle than is the uranium. The chemical element can notably be neptunium(IV) or thorium 228.